2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

909. Medical Education and Workforce Development: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research
PAPER

2854 Global trends in clinician readiness to integrate frontline BTK inhibitor strategies in mantle cell lymphoma: An extended longitudinal assessment

Carmine Deluca, BA, Michael Beyer, BS2, Marina Wanes, MS3, Andrea Corti, PhD4, Martin Dreyling, MD, PhD5, Toby A. Eyre, MBChB, DipMedEd, MRCP, MD6, Christine Ryan, MD7, Kami Maddocks, MD8, Carlo Visco, MD9, Pier Luigi Zinzani, MD, PhD10
1 PVI, PeerView Institute for Medical Education, New York, New York, United States
2 PVI, PeerView Institute for Medical Education, New York, New York, United States
3 PVI, PeerView Institute for Medical Education, New York, New York, United States
4 PVI, PeerView Institute for Medical Education, New York, New York, United States
5 LMU Hospital, Munich, Germany
6 Oxford University Hospitals, Oxford, United Kingdom
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 The Ohio State University, Columbus, Ohio, United States
9 University of Verona, Verona, Italy
10 University of Bologna, Bologna, Italy
Background: The modern frontline management of mantle cell lymphoma (MCL) is increasingly characterized by the first-line use of covalent BTK inhibitors (BTKi) as part of combination regimens while reflecting a re-evaluation of the role of autologous stem cell transplant (ASCT). Recent evidence supporting first-line use of BTKi has led to updated treatment guidelines in Europe and the United States, including for chemoimmunotherapy-inclusive and chemo-sparing options (Jerkeman M et al. HemaSphere. 2025;9:e70233; NCCN Guidelines B-Cell Lymphoma v4.2026; Dreyling M et al. Lancet. 2024;403:2293-2306; Wang M, et al. J Clin Oncol. 2025 Jul 10;43:2276-2284; Lewis D, et al. Lancet. 2025;406:1953-1968). We evaluated global trends in clinician preparedness to apply frontline BTKi-based strategies through a longitudinal educational outcomes analysis conducted between 2024 and 2026. Methods: A total of 4,812 hematologists and hematologist-oncologists participated in live and enduring educational programs (cohort 1) between June 2024 and June 2025 across North America (n=2,340), Europe (n=1,179), and Rest of World (n=693). Identical pre- and post-activity assessment questions evaluated knowledge and application of evidence-aligned frontline treatment strategies.  A follow-up live poll (December 2025; n=318, cohort 2) further assessed preparedness for frontline BTKi-based regimens in specific clinical scenarios; this was supplemented by surveys of an independent group of US clinicians (cohort 3) engaging in online learning modules (n=1,427) in 2026 (data cut-off, July 2026). Pre- and post-activity analyses quantified changes in evidence-concordant responses using all available responses for each assessment item across all cohorts. Logistic regression modelling evaluated the association between post-education status and selection of evidence-concordant strategies. Results: In cohort 1, selection of evidence-aligned frontline strategies increased by 36 percentage points, from 49% at baseline to 85% post-education. Post-education status was associated with greater odds of selecting an evidence-aligned strategy (odds ratio, 5.0; P<0.001). The largest improvement was observed among clinicians practicing outside North America and Europe, where evidence-aligned responses increased from 33% to 97% (P<0.05). Greater educational exposure was associated with incrementally larger gains in knowledge and skills, with improvements of 43% among participants completing 1-2 distinct activities and 48% among those completing 3-4 activities. In cohort 2, reported readiness to incorporate BTKi-chemoimmunotherapy combinations increased from 46% to 70% for ASCT-ineligible patients and from 35% to 69% for ASCT-eligible patients. In cohort 3, clinician preparedness increased across multiple domains, including application of current guidelines and efficacy/safety evidence for first-line BTKi regimens (41% to 89%), individualized treatment planning based on fitness, ASCT eligibility, and high-risk disease features (45% to 90%), and management of dose, treatment duration, and safety considerations for BTKi-containing regimens (35% to 83%). Conclusion: Longitudinal education was associated with improved selection of evidence-concordant frontline treatment strategies and greater self-reported preparedness to implement BTKi-based regimens for newly diagnosed MCL. Improvements were observed across geographic regions and were greater among clinicians completing multiple educational activities. Follow-up assessments in 2025 and 2026 demonstrated continued gains in applying contemporary evidence to individualized frontline treatment planning, while identifying persistent regional and implementation-readiness gaps. These findings suggest that sustained education may support more consistent application of evolving frontline MCL guidelines.
Carmine Deluca, BA: No relevant conflicts of interest to declare.